A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene

Clinical Immunology

Volumn 126, Issue 3, 2008, Pages 303-314

  King, Marie ^a   Pearson, Todd ^a   Shultz, Leonard D ^b   Leif, Jean ^a   Bottino, Rita ^c   Trucco, Massimo ^c   Atkinson, Mark A ^d   Wasserfall, Clive ^d   Herold, Kevan C ^e   Woodland, Robert T ^a   Schmidt, Madelyn R ^a   Woda, Bruce A ^a   Thompson, Michael J ^a   Rossini, Aldo A ^a   Greiner, Dale L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JACKSON LABORATORY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

Hu PBL SCID; Human; Humanized mice; IL 2r gamma chain; Islet; Mouse; NOD scid; Rejection; SCID; Transplantation

Indexed keywords

C PEPTIDE; INSULIN; INTERLEUKIN 2 RECEPTOR GAMMA; STREPTOZOCIN;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GENE MUTATION; GENE TARGETING; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNE DEFICIENCY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR GENE; REPRODUCIBILITY; SCID MOUSE; STEM CELL;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MUTATION; PHENOTYPE;

EID: 39149112228     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.11.001     Document Type: Article

References (44)

1. St Clair E.W., Turka L.A., Saxon A., Matthews J.B., Sayegh M.H., Eisenbarth G.S., and Bluestone J. New reagents on the horizon for immune tolerance. Annu. Rev. Med. 58 (2007) 329-346
2. Bresson D., and von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?. Autoimmun. Rev. 6 (2007) 315-322
3. von Herrath M.G., and Nepom G.T. Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J. Exp. Med. 202 (2005) 1159-1162
4. Leiter E.H., and Von Herrath M. Animal models have little to teach us about Type 1 diabetes: 2. In opposition to this proposal. Diabetologia 47 (2004) 1657-1660
5. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., Macleod M., Mignini L.E., Jayaram P., and Khan K.S. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334 (2007) 197
6. Talmadge J.E., Singh R.K., Fidler I.J., and Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 170 (2007) 793-804
7. Monk N.J., Hargreaves R.E., Simpson E., Dyson J.P., and Jurcevic S. Transplant tolerance: models, concepts and facts. J. Mol. Med. 84 (2006) 295-304
8. Roep B.O. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann. N.Y. Acad. Sci. 1103 (2007) 1-10
9. Greiner D.L., Rossini A.A., and Mordes J.P. Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: caveat emptor and primum non nocere. Clin. Immunol. 100 (2001) 134-143
10. Rossini A.A. From beast to bedside: a commentary. Diabetologia 47 (2004) 1647-1649
11. Bosma G.C., Custer R.P., and Bosma M.J. A severe combined immunodeficiency mutation in the mouse. Nature 301 (1983) 527-530
12. Mosier D.E., Gulizia R.J., Baird S.M., and Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335 (1988) 256-259
13. Greiner D.L., Hesselton R.A., and Shultz L.D. SCID mouse models of human stem cell engraftment. Stem Cells 16 (1998) 166-177
14. Shultz L.D., Schweitzer P.A., Christianson S.W., Gott B., Schweitzer I.B., McKenna S., Mobraaten L., Rajan T.V., Greiner D.L., and Leiter E.H. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154 (1995) 180-191
15. Hesselton R.M., Greiner D.L., Mordes J.P., Rajan T.V., Sullivan J.L., and Shultz L.D. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J. Infect. Dis. 172 (1995) 974-982
16. Shultz L.D., Ishikawa F., and Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7 (2007) 118-130
17. Legrand N., Weijer K., and Spits H. Experimental models to study development and function of the human immune system in vivo. J. Immunol. 176 (2006) 2053-2058
18. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., and Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304 (2004) 104-107
19. null mice engrafted with mobilized human hematopoietic stem cell. J. Immunol. 174 (2005) 6477-6489
20. Ishikawa F., Yasukawa M., Lyons B., Yoshida S., Miyamoto T., Yoshimoto G., Watanabe T., Akashi K., Shultz L.D., and Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain (null) mice. Blood 106 (2005) 1565-1573
21. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., Heike T., and Nakahata T. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100 (2002) 3175-3182
22. van Rijn R.S., Simonetti E.R., Hagenbeek A., Hogenes M.C., de Weger R.A., Canninga-van Dijk M.R., Weijer K., Spits H., Storm G., van Bloois L., Rijkers G., Martens A.C., and Ebeling S.B. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 102 (2003) 2522-2531
23. utis T.M., van Rijn R.S., Simonetti E.R., Aarts-Riemens T., Emmelot M.E., van Bloois L., Martens A., Verdonck L.F., and Ebeling S.B. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin. Cancer Res. 12 (2006) 5520-5525
24. null mice. Clin. Immunol. 112 (2004) 273-283
25. + T cell engraftment in b2-microglobulin-deficient NOD-scid mice. J. Immunol. 158 (1997) 3578-3586
26. Wagar E.J., Cromwell M.A., Shultz L.D., Woda B.A., Sullivan J.L., Hesselton R.M., and Greiner D.L. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J. Immunol. 165 (2000) 518-527
27. null mice: a new model system with increased levels of human peripheral leukocyte and hematopoietic stem-cell engraftment. Transplantation 76 (2003) 1036-1042
28. Greiner D.L., Shultz L.D., Yates J., Appel M.C., Perdrizet G., Hesselton R.M., Schweitzer I., Beamer W.G., Shultz K.L., Pelsue S.C., Leif J.H., and Rajan T.V. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am. J. Path. 146 (1995) 888-902
29. Gregori S., Mangia P., Bacchetta R., Tresoldi E., Kolbinger F., Traversari C., Carballido J.M., De Vries J.E., Korthauer U., and Roncarolo M.G. An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. J. Exp. Med. 201 (2005) 1293-1305
30. Amadori A., Veronesi A., Coppola V., Indraccolo S., Mion M., and Chieco-Bianchi L. The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Semin. Immunol. 8 (1996) 249-254
31. Turgeon N.A., Banuelos S.J., Shultz L.D., Lyons B.L., Iwakoshi N., Greiner D.L., Mordes J.P., Rossini A.A., and Appel M.C. Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice. Exp.Biol Medicine (Maywood) 228 (2003) 1096-1104
32. Greiner D.L., and Shultz L.D. Use of NOD/LtSz-scid/scid mice in biomedical research. In: Leiter E.H., and Atkinson M.A. (Eds). "NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancer and Other Diseases" (1998), R.G. Landes Co, Austin, TX 173-204
33. Christianson S.W., Greiner D.L., Schweitzer I.B., Gott B., Beamer G.L., Schweitzer P.A., Hesselton R.M., and Shultz L.D. Role of natural killer cells on engraftment of human lymphoid cells and on metastasis of human T-lymphoblastoid leukemia cells in C57BL/6J-scid mice and in C57BL/6J-scid bg mice. Cell. Immunol. 171 (1996) 186-199
34. van Rijn R.S., Simonetti E.R., Hagenbeek A., Bonyhadi M., Storm G., Martens A.C., and Ebeling S.B. Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality. Exp. Hematol. 35 (2007) 117-127
35. Hesselton R.M., Koup R.A., Cromwell M.A., Graham B.S., Johns M., and Sullivan J.L. Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J. Infect. Dis. 168 (1993) 630-640
36. Murphy W.J., Bennett M., Anver M.R., Baseler M., and Longo D.L. Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions. Eur. J. Immunol. 22 (1992) 1421-1427
37. Tournoy K.G., Depraetere S., Pauwels R.A., and Leroux-Roels G.G. Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice. Clin. Exp. Immunol. 119 (2000) 231-239
38. Lubin I., Segall H., Marcus H., David M., Kulova L., Steinitz M., Erlich P., Gan J., and Reisner Y. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood 83 (1994) 2368-2381
39. Murray A.G., Petzelbauer P., Hughes C.C.W., Costa J., Askenase P., and Pober J.S. Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immuno eficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 9146-9150
40. Murray A.G., Schechner J.S., Epperson D.E., Sultan P., McNiff J.M., Hughes C.C., Lorber M.I., Askenase P.W., and Pober J.S. Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin. Am. J. Pathol. 153 (1998) 627-638
41. Sultan P., Schechner J.S., McNiff J.M., Hochman P.S., Hughes C.C., Lorber M.I., Askenase P.W., and Pober J.S. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat. Biotechnol. 15 (1997) 759-762
42. Torbett B.E., Picchio G., and Mosier D.E. HuPBL/SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol. Rev. 124 (1991) 139-164
43. + T cell repertoire in hu-PBL-SCID chimeras. J. Exp. Med. 180 (1994) 1817-1827
44. Tary-Lehmann M., and Saxon A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J. Exp. Med. 175 (1992) 503-516